These data are consistent with other studies in which a novel Cadherin-like and PC-esterase domain containing 1 (CPED1) and Forkhead box protein P2 (FOXP2) fusion product (FOXP2-CPED1) was shown to confer oncogenic effects in prostate cancer (Zhu et al., 2023) and overexpression of CPED1 touted as a potential prognostic signature in stomach adenocarcinoma (Zhou et al., 2020). This evidence concerns the gene FOXP2 and Familial prostate cancer.